Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446464 | 0.83 | MAPT (0.50) | CNR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5454485 | 0.81 | ALOX15 (0.47) | CNR2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL5451215 | 0.79 | ADRA1D (0.45) | CNR2PIK3CAMTORPIK3CG | |
| SCHEMBL5454585 | 0.79 | CNR2 (0.47) | CNR2CNR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5448668 | 0.78 | ADRA1D (0.47) | CNR2ALDH1A1GAALMNA | |
| SCHEMBL5454553 | 0.78 | HTR2A (0.47) | CNR2CNR1ALDH1A1MEN1KMT2A | |
| SCHEMBL14412213 | 0.78 | HTR1A (0.51) | CNR2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL5446507 | 0.77 | CNR1 (0.64) | CNR2CNR1RAB9AALDH1A1GAA | |
| SCHEMBL5452683 | 0.77 | SLC6A2 (0.53) | MEN1KMT2A | |
| SCHEMBL5441664 | 0.76 | CNR2 (0.45) | CNR2CNR1RAB9APIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885CNR1 65/4885RAB9A 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.